WCM
VNDA icon

Westend Capital Management’s Vanda Pharmaceuticals VNDA Stock Holding History

Westend Capital Management’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-64,086
Closed -$841K – 105
2014
Q2 		$841K Buy
+64,086
New +$854K 1% 35

Other funds holding VNDA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
SCA
Signpost Capital Advisors New York $34.2M AUM 5.08% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Westend Capital Management's VNDA Position: Q3 2014 in Review

Westend Capital Management sold out of Vanda Pharmaceuticals (VNDA) in Q3 2014, closing a stake of 64,086 shares — an estimated $841K sold.

Westend Capital Management first reported a position in VNDA in Q2 2014 and held it in 1 quarter. The position peaked at $841K in Q2 2014. 101 funds tracked by Wall St. Rank hold VNDA as of Q3 2014.

  • Westend Capital Management reported no remaining Vanda Pharmaceuticals position as of Q3 2014 after selling out during the quarter.
  • Westend Capital Management sold 64,086 Vanda Pharmaceuticals shares in Q3 2014, an estimated $841K.
  • Westend Capital Management first reported a position in Vanda Pharmaceuticals in Q2 2014 and held it in 1 quarter.
  • Westend Capital Management's Vanda Pharmaceuticals position peaked at $841K in Q2 2014.
  • 101 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q3 2014.

Based on Westend Capital Management's 13F filing for Q3 2014, filed 12 Nov 2014.